Zynex, Inc. (“Zynex”) (Nasdaq: ZYXI), today announced that Thomas Sandgaard , its Chief Executive Officer (the “Selling Stockholder”), has determined not to pursue the public offering of 2,000,000 shares of the Company’s common stock that was previously announced on May 3, 2023 (the “Secondary Offering”).
Zynex Announces Update Regarding Previously Announced Offerings Read More »
NuVasive, Inc. announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market.
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results Read More »
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2023.
Poco a poco, la realidad virtual va abriéndose paso en campos como el de los videojuegos y el educativo. Sin embargo, el uso de realidad virtual puede tener efectos secundarios. De entre ellos, el más común es un mareo que, por su origen, se ha dado en llamar “cibermareo&r …
El cibermareo provocado por el uso de realidad virtual Read More »
Un nuevo estudio documenta la primera observación clara de una estrella envejecida que se traga un planeta. Tras quedarse sin combustible en su núcleo, la estrella comenzó a crecer en tamaño, reduciendo la distancia con su planeta vecino, para finalmente engullirlo. Dentr …
En este Short queremos saber cuánto puede prolongarse la longevidad humana. …
Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results Read More »
NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m.
NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023 Read More »
Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced positive results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease.
InfuSystem Holdings, Inc., a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, reported financial results for the first quarter ended March 31, 2023.
InfuSystem Reports First Quarter 2023 Financial Results Read More »
